Australian court orders Nurofen’s specific pain range off the shelvesBMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h6852 (Published 16 December 2015) Cite this as: BMJ 2015;351:h6852
- Amy Coopes
Reckitt Benckiser (RB), the health and hygiene multinational, has been ordered to recall from Australian stockists a suite of ibuprofen products that claim to relieve specific types of pain after a court found it guilty of misleading and deceptive conduct.
The Federal Court of Australia ordered RB to remove its Nurofen “specific pain” range from retail shelves after the multinational admitted contravening Australian consumer law by advertising the products as able to target distinct types and sites of pain.1
Justice James Edelman ruled that all four products in the targeted Nurofen range—for tension headache, period pain, migraine pain, and back pain—were in fact identical, each containing ibuprofen lysine 342 mg. None of the products was “any more or less effective than the others in treating any of the symptoms shown on the packaging,” Edelman said in his …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial